CMS

CHINA MEDICAL SYSTEM HOLDINGS LIMITED collaborates with global biotech (or pharmaceutical) companies to co-develop First-in-Class (FIC) and Best-in-Class* (BIC) innovative products. By building an open, cooperative, and win-win healthcare innovation ecosystem, we enhance the efficiency of pharmaceutical R&D. Equipped with a management system and professional team that oversee key milestones across the entire lifecycle of innovative products, extensive expert resources in specialized disease areas, robust self-owned cash flow, and deep market insights, we identify and develop products that address unmet clinical needs while expediting the clinical development and commercialization of innovative solutions. We empower the continuous transformation of scientific research into clinical practice, benefiting more patients. With a focus on specialized therapeutic areas such as cardiovascular, cerebrovascular, gastroenterology, central nervous system, dermatology, ophthalmology, and pediatrics, our leading marketed products have achieved prominent market positions, driving over 20% compound annual growth rates in both sales and net profit for the Group over the past fifteen years. Additionally, through independent operations in specialized verticals, we further integrate premium resources within specialized disease fields, fostering high-caliber teams with focus and intrinsic motivation. Leveraging synergies and shared resources at the group level, we enhance operational efficiency in specialized businesses, cultivating leaders in niche markets. Meanwhile, our business footprint has expanded to Southeast Asia, positioning us as a "bridgehead" for global pharmaceutical companies entering the Southeast Asian market and promoting high-quality, sustainable growth for the Group.